Scott M. Lippman, MD, brings more than 25 years of experience as principal investigator of translational research involving investigator-initiated clinical trials and maintains an active clinical practice. As a clinician, he is well-respected by his peers, with recognition in every major “Top Doctor” listing including U.S. News & World Report. His research interests include clinical and translational research focused on head and neck and lung cancer; genetic drivers of cancer; predictive molecular signatures, biomarkers for clinical response in solid tumors; design of trials using molecular targets and markers for cancer prevention and therapy. Since 1990, he has had continuous funding from the National Cancer Institute (NCI), including as principal investigator of major programmatic grants to develop personalized or precision medicine. He received The University of Texas MD Anderson Cancer Center team science award for his leadership of the multidisciplinary molecular-guided Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial for lung cancer. Dr. Lippman is Director of Moores Cancer Center at UC San Diego Health, the only NCI-designated comprehensive cancer center in the region. He is Senior Associate Dean and Associate Vice Chancellor for Cancer Research and Care, Professor of Medicine, Chugai Pharmaceutical Chair and adjunct professor at the Salk Institute for Biological Studies, Sanford Burnham Prebys Medical Discovery Institute and MD Anderson Cancer Center. Prior to arriving at Moores Cancer Center in 2012, Dr. Lippman was chair of the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center.
Sessions
NACCDO: Board Leadership Conundrums, Rebuilding, Revising and Moving Forward